Demonstrated to significantly reduce stroke compared to warfarin, Pradaxa is first new oral anticoagulant approved by the FDA in more than 50 years RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- The U.S.
Please provide your email address to receive an email when new articles are posted on . The FDA has announced approval of dabigatran etexilate for the prevention of stroke and blood clots in patients ...
RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...
Since its approval in the United States in October 2010 dabigatran (Pradaxa) has been prescribed 3.2 million times to more than 600,000 patients with nonvalvular atrial fibrillation (AF), according to ...
“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa ® can offer patients with atrial fibrillation and their treating physicians; a benefit which has ...
(Updated August 30, 2009) (Barcelona, Spain) — An oral anticoagulant that does not go by the name of warfarin prevented strokes and peripheral embolic events in patients with atrial fibrillation (AF) ...
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared the efficacy and safety of dabigatran (Pradax in Canada and Pradaxa in Europe), a new oral direct thrombin ...
In 2010, the blood thinner dabigatran (brand name Pradaxa) was approved by the U.S. Food and Drug Administration as a treatment option for people with atrial fibrillation. Dabigatran was at least as ...
Blockbuster blood-thinner Pradaxa will come under scrutiny again, it appears. The FDA announced last Friday that it has established a study to evaluate post-trial safety outcomes in blood-thinning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results